U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07490535) titled 'This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra(R) (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye' on March 18.
Brief Summary: This is a single-center prospective open-label, clinical trial to explore proteomic expression of tear fluid biomarkers in patients with dry eye treated with Lifitegrast.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Ocular Surface Disease
Dry Eye Syndrome (DES)
Intervention:
DRUG: (Xiidra(R)) Lifitegrast Ophthalmic Solution 5.0%
30 DED subjects will receive (Xiidra(R)) lifitegrast ophthalmic solution 5.0%
Recrui...